Benefit-Risk Assessment Methods in Medical Product Development
Bridging Qualitative and Quantitative Assessments
CHF 69.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
V210:
Noch nicht erschienen, Januar 2021
Produktdetails
Weitere Autoren: He, Weili (Hrsg.)
- ISBN: 978-0-367-73708-5
- EAN: 9780367737085
- Produktnummer: 34927463
- Verlag: Taylor and Francis
- Sprache: Englisch
- Erscheinungsjahr: 2020
- Seitenangabe: 312 S.
- Masse: H25.4 cm x B17.8 cm
- Abbildungen: Farb., s/w. Abb.
Über den Autor
Dr. Qi Jiang is an executive director of Global Biostatistical Science at Amgen. In this role, she is the biostatistical therapeutic area head for oncology and hematology and the lead of the Center of Excellence for Safety and Benefit-Risk. In addition, Dr. Jiang provides oversight to Amgen's biostatistical efforts in the Asia-Pacific region. Before joining Amgen, she worked at the Harvard School of Public Health, Merck, and Novartis. Dr. Jiang is the co-editor of the Chapman & Hall/CRC book Quantitative Evaluation of Safety in Drug Development: Design, Analysis and Reporting and the author of more than 60 peer-reviewed publications on method development, study design, and data analysis and reporting. She is a fellow of the American Statistical Association, a co-lead of the American Statistical Association Biopharmaceutical Section Safety Working Group, a co-lead of the Quantitative Sciences in the Pharmaceutical Industry (QSPI) Benefit-Risk Working Group, and an associate editor for Statistics in Biopharmaceutical Research.Dr. Weili He is a director of clinical biostatistics at Merck & Co., Inc. Her research interests include survival and longitudinal data modeling, missing data imputation, cancer Phase I and II designs, repeated categorical data modeling, surrogate marker evaluations, adaptive design methodologies and implementations, and methods for benefit-risk assessment. Dr. He has published extensively in the areas of adaptive designs and benefit-risk evaluations and is the author of more than 50 peer-reviewed publications in statistical and medical journals. She is also a lead editor of the book Practical Considerations for Adaptive Trial Design and Implementation. She has been actively involved in many professional activities and services, including serving as co-chair of the Quantitative Sciences in the Pharmaceutical Industry (QSPI) Benefit-Risk Working Group, co-chair of the DIA Adaptive Design Scientific Working Group (ADSWG) KOL lecture series, associate editor for Statistics in Biopharmaceutical Research, and a referee for other statistical journals.
6 weitere Werke von Qi (Hrsg.) Jiang:
Bewertungen
Anmelden